Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.

You may also be interested in...



White Paper Is Actually Branded Promotion, FDA Tells Ipsen

Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.

White Paper Is Actually Branded Promotion, FDA Tells Ipsen

Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.

Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal

A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel